OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol
Acta Oncol
.
2022 Sep;61(9):1152-1156.
doi: 10.1080/0284186X.2022.2116728.
Epub 2022 Sep 12.
Authors
Louise Bach Callesen
1
,
Torben Frøstrup Hansen
2
,
Rikke Fredslund Andersen
3
,
Niels Pallisgaard
4
,
Stine Kramer
5
,
Sven Schlander
6
,
Søren Rafael Rafaelsen
7
,
Anders Kindberg Boysen
1
,
Lars Henrik Jensen
2
,
Anders Jakobsen
2
,
Karen-Lise Garm Spindler
1
Affiliations
1
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
2
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
3
Department of Biochemistry and Immunology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
4
Department of Pathology, Zealand University Hospital, Roskilde, Denmark.
5
Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital, Aarhus, Denmark.
6
Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
7
Department of Radiology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
PMID:
36094310
DOI:
10.1080/0284186X.2022.2116728
No abstract available
Publication types
Clinical Trial Protocol
MeSH terms
Circulating Tumor DNA*
Clinical Trials, Phase II as Topic
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Follow-Up Studies
Humans
Patient Selection
Substances
Circulating Tumor DNA